Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
6.99
-0.02 (-0.29%)
At close: Nov 21, 2025, 4:00 PM EST
6.97
-0.02 (-0.29%)
After-hours: Nov 21, 2025, 7:51 PM EST
Nuvation Bio Revenue
Nuvation Bio had revenue of $13.12M in the quarter ending September 30, 2025, with 1,704.68% growth. This brings the company's revenue in the last twelve months to $26.75M, up 1,137.19% year-over-year. In the year 2024, Nuvation Bio had annual revenue of $7.87M.
Revenue (ttm)
$26.75M
Revenue Growth
+1,137.19%
P/S Ratio
88.80
Revenue / Employee
$121,582
Employees
220
Market Cap
2.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.87M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
NUVB News
- 1 day ago - Nuvation Bio Inc. (NUVB) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 15 days ago - Nuvation Bio: Ibtrozi's Rollout So Far Confirms Bullish Case - Seeking Alpha
- 19 days ago - Nuvation Bio Inc. (NUVB) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 19 days ago - Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 23 days ago - Nuvation Bio to Participate in Upcoming Investor Conferences - Business Wire
- 4 weeks ago - Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma - Business Wire
- 4 weeks ago - Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025 - Business Wire
- 7 weeks ago - Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer - Business Wire